Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus (Q40701437)

22 September 2017

Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus (English)

1 reference

22 September 2017

David L Evers

1

1 reference

22 September 2017

Gloria Komazin

2

1 reference

22 September 2017

Dongjin Shin

3

1 reference

22 September 2017

Debbie D Hwang

4

1 reference

22 September 2017

Leroy B Townsend

5

1 reference

22 September 2017

John C Drach

6

1 reference

22 September 2017

1 October 2002

1 reference

22 September 2017

1 reference

22 September 2017

56

1 reference

22 September 2017

1

1 reference

22 September 2017

61-72

1 reference

Interaction of the herpes simplex virus type 1 packaging protein UL15 with full-length and deleted forms of the UL28 protein

22 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

The gene product of human cytomegalovirus open reading frame UL56 binds the pac motif and has specific nuclease activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Treatment of aggressive cytomegalovirus retinitis with ganciclovir in combination with foscarnet in a child infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Treatment of cytomegalovirus retinitis with ganciclovir and foscarnet

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Foscarnet nephrotoxicity: mechanism, incidence and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

"The end of innocence" revisited: resistance of herpesviruses to antiviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

The potential terminase subunit of human cytomegalovirus, pUL56, is translocated into the nucleus by its own nuclear localization signal and interacts with importin alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

ATPase activity of the terminase subunit pUL56 of human cytomegalovirus.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Cidofovir in the treatment of cytomegaloviral disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Differences in DNA packaging genes and sensitivity to benzimidazole ribonucleosides between human cytomegalovirus strains AD169 and Towne.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Simultaneous treatment of cytomegalovirus retinitis with ganciclovir and foscarnet

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Potential infectious etiologies of atherosclerosis: a multifactorial perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

A three-dimensional model to analyze drug-drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

A microtiter virus yield reduction assay for the evaluation of antiviral compounds against human cytomegalovirus and herpes simplex virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Three-dimensional analysis of the synergistic cytotoxicity of ganciclovir and zidovudine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Synthesis of non-nucleoside analogs of toyocamycin, sangivamycin, and ++thiosangivamycin: influence of various 7-substituents on antiviral activity

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

The terminase subunits pUL56 and pUL89 of human cytomegalovirus are DNA-metabolizing proteins with toroidal structure

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Evaluation of 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic Acid (HEPES) as a Tissue Culture Buffer

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(beta-D-ribofuranosyl)benzimidazoles

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Studies designed to increase the stability and antiviral activity (HCMV) of the active benzimidazole nucleoside, TCRB

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Pyrrolo[2,3-d]pyrimidine nucleosides as inhibitors of human cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleosidic compound in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

Combined antiviral effects of paired nucleosides against guinea pig cytomegalovirus replication in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2802%2900094-3

7 January 2021

10.1016/S0166-3542(02)00094-3

Identifiers

DOI

1 reference

22 September 2017

1 reference